Limits...
High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer.

Oh J, Park SH, Lee TS, Oh HK, Choi JH, Choi YS - J Gynecol Oncol (2014)

Bottom Line: We analyzed the correlations between the expression of EGFL7 and various clinical parameters, and also analyzed the survival outcome according to the EGFL7 expression.Among these clinicopathologic factors, differentiation was significantly correlated with EGFL7 expression in multivariate analysis (p<0.05).Survival analysis showed that the patients with high EGFL7 expression had a poorer disease free survival than those with low EGFL7 expression (p=0.002).

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, Daegu, Korea.

ABSTRACT

Objective: The purpose of this study was to evaluate the expression of epidermal growth factor-like domain 7 (EGFL7) in epithelial ovarian cancer, and to assess its relevance to clinicopathological characteristics and patients' survival.

Methods: A total of 177 patients with epithelial ovarian cancer were enrolled in the current study. For each patient, a retrospective review of medical records was conducted. Immunohistochemical staining for EGFL7 was performed using tissue microarrays made with paraffin-embedded tissue block. EGFL7 expression levels were graded on a grade of 0 to 3 based on the percentage of positive cancer cells. We analyzed the correlations between the expression of EGFL7 and various clinical parameters, and also analyzed the survival outcome according to the EGFL7 expression.

Results: The expression of EGFL7 in ovarian cancer tissues was observed in 98 patients (55.4%). High expression of EGFL7 (grade 2 or 3) was significantly correlated with pathologic type, differentiation, stage, residual tumor after debulking surgery, lymphovascular space involvement, lymph node metastasis, high cancer antigen 125, peritoneal cytology, and ascites. Among these clinicopathologic factors, differentiation was significantly correlated with EGFL7 expression in multivariate analysis (p<0.05). Survival analysis showed that the patients with high EGFL7 expression had a poorer disease free survival than those with low EGFL7 expression (p=0.002).

Conclusion: Our data suggest that EGFL7 expression is a novel predictive factor for the clinical progression of epithelial ovarian cancer, and may constitute a therapeutic target for antiangiogenesis therapy in patients with epithelial ovarian cancer.

Show MeSH

Related in: MedlinePlus

Survival analysis according to the epidermal growth factor-like domain 7 (EGFL7) expression (low EGFL7 expression [grade 0 or 1] vs. high EGFL7 expression [grade 2 or 3]). Kaplan-Meier analysis showed that the patients with high EGFL7 expression had a poorer disease-free survival than those with low EGFL7 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4195305&req=5

Figure 2: Survival analysis according to the epidermal growth factor-like domain 7 (EGFL7) expression (low EGFL7 expression [grade 0 or 1] vs. high EGFL7 expression [grade 2 or 3]). Kaplan-Meier analysis showed that the patients with high EGFL7 expression had a poorer disease-free survival than those with low EGFL7 expression.

Mentions: Survival analysis showed that age, stage, differentiation, optimal debulking, lymph node metastasis, high serum CA-125, LVSI, peritoneal cytology, ascites, and pathologic type were significantly correlated with overall and disease free survival (Table 2). Survival analysis showed that the patients with high EGFL7 expression had a poorer DFS than those with low EGFL7 expression (p=0.002) (Fig. 2). A similar tendency for difference in survival was observed in OS, but the difference did not reach statistical significance (p=0.142) (Table 2). However, Cox multivariate regression analysis showed that EGFL7 expression was not an independent prognostic factor (Table 3).


High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer.

Oh J, Park SH, Lee TS, Oh HK, Choi JH, Choi YS - J Gynecol Oncol (2014)

Survival analysis according to the epidermal growth factor-like domain 7 (EGFL7) expression (low EGFL7 expression [grade 0 or 1] vs. high EGFL7 expression [grade 2 or 3]). Kaplan-Meier analysis showed that the patients with high EGFL7 expression had a poorer disease-free survival than those with low EGFL7 expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4195305&req=5

Figure 2: Survival analysis according to the epidermal growth factor-like domain 7 (EGFL7) expression (low EGFL7 expression [grade 0 or 1] vs. high EGFL7 expression [grade 2 or 3]). Kaplan-Meier analysis showed that the patients with high EGFL7 expression had a poorer disease-free survival than those with low EGFL7 expression.
Mentions: Survival analysis showed that age, stage, differentiation, optimal debulking, lymph node metastasis, high serum CA-125, LVSI, peritoneal cytology, ascites, and pathologic type were significantly correlated with overall and disease free survival (Table 2). Survival analysis showed that the patients with high EGFL7 expression had a poorer DFS than those with low EGFL7 expression (p=0.002) (Fig. 2). A similar tendency for difference in survival was observed in OS, but the difference did not reach statistical significance (p=0.142) (Table 2). However, Cox multivariate regression analysis showed that EGFL7 expression was not an independent prognostic factor (Table 3).

Bottom Line: We analyzed the correlations between the expression of EGFL7 and various clinical parameters, and also analyzed the survival outcome according to the EGFL7 expression.Among these clinicopathologic factors, differentiation was significantly correlated with EGFL7 expression in multivariate analysis (p<0.05).Survival analysis showed that the patients with high EGFL7 expression had a poorer disease free survival than those with low EGFL7 expression (p=0.002).

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, Daegu, Korea.

ABSTRACT

Objective: The purpose of this study was to evaluate the expression of epidermal growth factor-like domain 7 (EGFL7) in epithelial ovarian cancer, and to assess its relevance to clinicopathological characteristics and patients' survival.

Methods: A total of 177 patients with epithelial ovarian cancer were enrolled in the current study. For each patient, a retrospective review of medical records was conducted. Immunohistochemical staining for EGFL7 was performed using tissue microarrays made with paraffin-embedded tissue block. EGFL7 expression levels were graded on a grade of 0 to 3 based on the percentage of positive cancer cells. We analyzed the correlations between the expression of EGFL7 and various clinical parameters, and also analyzed the survival outcome according to the EGFL7 expression.

Results: The expression of EGFL7 in ovarian cancer tissues was observed in 98 patients (55.4%). High expression of EGFL7 (grade 2 or 3) was significantly correlated with pathologic type, differentiation, stage, residual tumor after debulking surgery, lymphovascular space involvement, lymph node metastasis, high cancer antigen 125, peritoneal cytology, and ascites. Among these clinicopathologic factors, differentiation was significantly correlated with EGFL7 expression in multivariate analysis (p<0.05). Survival analysis showed that the patients with high EGFL7 expression had a poorer disease free survival than those with low EGFL7 expression (p=0.002).

Conclusion: Our data suggest that EGFL7 expression is a novel predictive factor for the clinical progression of epithelial ovarian cancer, and may constitute a therapeutic target for antiangiogenesis therapy in patients with epithelial ovarian cancer.

Show MeSH
Related in: MedlinePlus